Hangzhou Heda Financial Services

Jin Yufeng serves as Chairman and General Manager of the group, holding ultimate responsibility for investment decisions and strategic direction per public record. His role spans both the financial services entity and its alignment with municipal development objectives under the Qiantang New Area Management Committee.

The Qiantang New Area Management Committee is the ultimate controlling entity of the group, making Hangzhou Heda Financial Services a de facto municipal investment platform. This governance structure means investment priorities are directly aligned with the economic development goals of Hangzhou's Qiantang New Area, including the build-out of the Qiantang China Pharmaceutical Port.

Proprietary deal flow is intrinsically linked to its position within the Qiantang New Area ecosystem. The Qiantang China Pharmaceutical Port serves as both a sourcing channel and a destination for portfolio companies, giving the firm preferential visibility into ventures that align with the region's targeted life science and technology clusters.

The firm operates dedicated investment vehicles including the Heda Industry Fund and the Heda Xinyiyao fund, the latter established in partnership with Bank of Hangzhou per public record. These funds execute direct venture investments, though the structural specifics regarding LP commitments from external parties remain undisclosed.

The firm is active across the full venture continuum, from early-stage seed and start-up rounds through expansion and late-stage growth equity. This broad mandate supports the regional strategy of populating Qiantang's industrial parks with companies at multiple maturity levels, particularly within the healthcare and life science sectors.

Bank of Hangzhou is a business partner in the Heda Xinyiyao investment entity, a dedicated fund vehicle named for its healthcare mandate. This partnership connects the municipal investment strategy with balance sheet and financial infrastructure from one of Hangzhou's key regional banks.

The Qiantang China Pharmaceutical Port is the anchor industrial asset complementing the Heda Xinyiyao fund. The firm invests in life science companies that can occupy and scale within this dedicated industrial park, creating a vertically integrated model where investment returns and physical commercial development are mutually reinforcing.